NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/28/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,161.83 mln
Float70.53 mln
Earnings Date10/29/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-2.94
Likely reliable
1-Year Forecast
32.00
Transformational upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.50
Moderate leverage
ROE
-169
Deeply negative
Business Description
Kura Oncology is a San Diego-based pharmaceutical company focused on developing new treatments for cancer and other serious diseases. Its first approved drug, KOMZIFTI, targets a specific protein involved in cancer growth and is taken by mouth. The company is also running early-stage trials for darlifarnib, testing it alongside other treatments for patients with solid tumors, while advancing a newer compound called KO-7246 aimed at diabetes and heart-related conditions.
